Perspective
Nature Reviews Drug Discovery 7, 563-567 (July 2008) | doi:10.1038/nrd2594
Outlook: What drives success for specialty pharmaceuticals?
Mark Gudiksen1, Edd Fleming1, Laura Furstenthal1 & Philip Ma1 About the authors
Top of page
Abstract
Specialty pharmaceuticals have become increasingly important in the global pharmaceutical landscape. Numerous large pharmaceutical companies are moving towards developing therapies for specialty markets, which are attractive owing to factors including the established commercial track record and lower commercial infrastructure costs. In this article, we analyse the key drivers of commercial success and failure for specialty pharmaceuticals.
Author affiliations
- All the authors are at McKinsey & Company, 3075A Hansen Way, Palo Alto, California 94304, USA.
Correspondence to: Philip Ma1 Email: Philip_Ma@mckinsey.com
